The 2025-2026 US Peptide Market Collapse: What Fell, What Survived, and the New Bar for COAs

The scale of the shakeout

Between late 2025 and September 2026, the US-facing research peptide market lost at least nine significant vendors. Unlike earlier rounds of 503A list churn, which moved substance-by-substance through rulemaking, this contraction was driven simultaneously by enforcement, private litigation, and public re-testing — a three-front squeeze.

The closures, as documented (primary compilation via The Peptide Catalog’s ongoing vendor-shutdown series):

• Peptide Sciences — at ~$7.4M monthly sales arguably the largest US research catalog, went offline overnight on March 6, 2026, with no public post-mortem.
• Paradigm Peptides — founder sentenced to 70 months in federal prison with $5M forfeiture; the charge sheet included falsified certificates of analysis.
• Amino Asylum — FDA enforcement seizure.
• Strate Labs, Science.bio and five-plus others — shutdowns or exits under legal pressure, including Eli Lilly’s litigation line against GLP-1 sellers (Novo Nordisk separately named 14 distribution accounts in one suit).

Three enforcement forces

1. Machine-reading of “research only” language. FDA scrutiny reportedly uses automated crawlers to flag pages whose text — dosage tables, “how many units,” titration graphics — implies human administration regardless of RUO boilerplate. The disclaimer is no longer the test; the page is.
2. Brand-owner litigation. Lilly and Novo have converted patent-adjacent claims into a distributor-choking campaign aimed precisely at semaglutide/tirzepatide catalog pages.
3. The third-party-testing economy turning on its subjects. Independent labs and public testers (the Janoshik model) now routinely re-test marketed batches — and publish mismatches. A COA that can’t survive a re-test is an advertised liability.

What survival now looks like

The survivors share a profile the dead did not: published, lot-traceable, independently named COAs, GLP-1 pages handled with visible caution, and supply redundancy — several have publicly positioned as seeking second manufacturing sources after watching single-supplier peers die mid-quarter. Retail pricing on hot compounds held firm or rose through the collapse (BPC-157 ~$4.90/mg, tirzepatide ~$3.17/mg at surviving US storefronts as of September 2026), which tells you demand didn’t shrink — only the qualified supply did.

For our own wholesale readers, the collapse is one brutal editorial on what we’ve always listed as table stakes: batch-level HPLC, named independent lab, QR-verifiable history. The COA reading guide and supplier selection framework predate this event but now read like a checklist written by the survivors.

What we expect next

Three predictions held to light evidence: (1) enforcement pressure migrates to EU/UK storefronts as US retail consolidates; (2) “survived the 2026 shakeout” becomes a marketing category within two quarters — watch for it; (3) the verifiable-COA bar, once a differentiator, becomes mere admission pricing to the market by 2027.

This article documents public market events for supply-chain research. Named entities’ legal statuses are summarized from cited public reporting; nothing here is legal advice.